drugset / Trial / NCT01744340
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
Phase 1/2
Completed
23 enrolled
Howard Safran
Fatima Memorial Hospital · collabMontefiore Medical Center · collabRhode Island Hospital · collabThe Miriam Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the full dose of eribulin mesylate can be safely given with the full dose of cetuximab. The activity of the combination of eribulin mesylate and cetuximab on recurrent head and neck cancer and colon cancer will also be assessed.
Timeline
- Start
- 2012-05
- Primary completion
- 2015-03
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |
| Subject | Eribulin | Small molecule | 0.7 mg/m2 | Intravenous |
| Subject | Eribulin | Small molecule | 1 mg/m2 | Intravenous |
| Subject | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |